Case Study
Identification of highly potent and selective Interleukin-1 receptor
Kymera has developed first in class selective and potent IRAK4 degraders. IRAK4 degraders are highly effective and superior to SMI at inhibiting myddosome signaling and blocking cytokine/chemokine induction by TLR agonists and IL-1.